BRWA
AMAM

B. Riley Wealth Advisors’s Ambrx Biopharma Inc AMAM Stock Holding History

B. Riley Wealth Advisors’s Portfolio AMAM Stock Details AMAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-20,000
Closed -$45.4K – 1629
2022
Q4 		$45.4K Buy
+20,000
New +$22.9K ﹤0.01% 1418

Other funds holding AMAM

DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

B. Riley Wealth Advisors's AMAM Position: Q1 2023 in Review

B. Riley Wealth Advisors sold out of Ambrx Biopharma Inc (AMAM) in Q1 2023, closing a stake of 20,000 shares — an estimated $45.4K sold.

B. Riley Wealth Advisors first reported a position in AMAM in Q4 2022 and held it in 1 quarter. The position peaked at $45.4K in Q4 2022. 30 funds tracked by Wall St. Rank hold AMAM as of Q1 2023.

  • B. Riley Wealth Advisors reported no remaining Ambrx Biopharma Inc position as of Q1 2023 after selling out during the quarter.
  • B. Riley Wealth Advisors sold 20,000 Ambrx Biopharma Inc shares in Q1 2023, an estimated $45.4K.
  • B. Riley Wealth Advisors first reported a position in Ambrx Biopharma Inc in Q4 2022 and held it in 1 quarter.
  • B. Riley Wealth Advisors's Ambrx Biopharma Inc position peaked at $45.4K in Q4 2022.
  • 30 funds tracked by Wall St. Rank held Ambrx Biopharma Inc as of Q1 2023.

Based on B. Riley Wealth Advisors's 13F filing for Q1 2023, filed 17 May 2023.